Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the management of lower urinary tract symptoms, highlighting drug therapy advancements that have reduced the frequency of surgical interventions.

This review discusses the sexual side effects of medical and surgical treatments for benign prostatic hyperplasia, such as erectile dysfunction and changes in ejaculation, but presents no new clinical findings.

This review found that finasteride monotherapy for managing LUTS/BPH significantly reduced prostate volume and improved symptoms, with sexual dysfunctions reported as notable side effects compared to placebo, but emphasizes the need for more comprehensive studies.

Taking dutasteride every other day works as well as daily and better preserves sexual function.

In this retrospective study, researchers found that coadministration of finasteride and sildenafil in patients with benign prostatic hyperplasia improved both lower urinary tract symptoms and sexual function, without significant changes in vital signs, after a treatment period averaging 18 weeks.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

In this study, short-term treatment with lovastatin showed no effect on symptom severity, prostate volume, or PSA levels in men with prostatic enlargement from presumed benign prostatic hyperplasia.

Dutasteride, fesoterodine, and finasteride help older patients with urinary issues.

This review discusses recent advancements and new approvals in the medical treatment of lower urinary tract symptoms, particularly highlighting drugs for nocturia and ongoing trials for multiple related conditions, while reporting no new clinical results.

This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.

This study found that after 12 months of treatment with 5 mg of finasteride, patients with benign prostatic hyperplasia showed reduced prostate volume, DHT and PSA levels, and improved urinary flow rates and symptoms.

This study demonstrated that the IVL-DrugFluidic® platform is effective for mass-producing finasteride-loaded polymeric microspheres for long-acting injectables, maintaining stable drug release without an initial burst for a month.

More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.

This review discusses the challenges in developing combination therapies for urological conditions and notes that regulatory requirements and financial disincentives hinder progress, without presenting new clinical findings.

This study found that dutasteride improved maximum urinary flow rate more effectively than finasteride when used in combination therapy with tamsulosin for treating benign prostatic hyperplasia over six months.

This study found no significant difference between alpha-blockers and finasteride in contributing to erectile dysfunction among men with other risk factors, with age and other underlying conditions being stronger influences.

This study analyzed data from the FDA Adverse Event Reporting System and found that finasteride had the highest reporting frequency and signal strength for drug-induced erectile dysfunction among 734 drugs, with compound preparations posing higher risks than single ingredients.

Entadfi, a mix of finasteride and tadalafil, is used for BPH.

This article discusses the newly approved drug dutasteride for managing benign prostatic hyperplasia, but reports no new research findings; the authors advise obtaining complete information before prescribing.

This review discusses the potential risks of ejaculatory dysfunction associated with both medical and surgical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and their implications for male fertility, but it reports no new clinical results.

This study concluded that finasteride is a viable first-line treatment for moderate uncomplicated benign prostatic hyperplasia, particularly in patients with larger prostates, by significantly reducing acute urinary retention and the need for surgery.

This study suggests that flibanserin may have a similar safety profile in men to that observed in premenopausal women, with positive responses reported for various sexual dysfunctions, but further research is needed.

This study describes a new LC-MS/MS method for analyzing Finasteride and Tadalafil, demonstrating system suitability, linearity, and accuracy in pharmacokinetic studies in rats, aligning with USFDA guidelines.